2021
Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCost-Benefit AnalysisFemaleHumansMaleMiddle AgedConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rateCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsCost-Benefit AnalysisHumansMaleProstatic NeoplasmsQuality-Adjusted Life YearsRadiotherapyTumor BurdenConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspective
2013
Interpreting cost-utility analysis of prostate cancer treatment
Yu J. Interpreting cost-utility analysis of prostate cancer treatment. Nature Reviews Urology 2013, 10: 129-131. PMID: 23399726, DOI: 10.1038/nrurol.2013.17.Peer-Reviewed Original Research
2010
Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis
Raldow A, Hamstra D, Kim S, Yu J. Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis. Cancer Treatment Reviews 2010, 37: 89-96. PMID: 20667660, DOI: 10.1016/j.ctrv.2010.07.001.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisHumansMaleProstatectomyProstatic NeoplasmsRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSalvage TherapyConceptsTarget volumeIncreased risk of cancer recurrencePositive surgical marginsSeminal vesicle invasionTreatment target volumeLocalized prostate cancerRisk of cancer recurrenceSigns of recurrenceTreatment of patientsTechnical aspects of treatmentDecrease side effectsRandomized clinical trialsUndetectable PSAAdjuvant radiotherapyAdjuvant settingDose escalationExtracapsular extensionRadical prostatectomySurgical marginsRadiation therapyProstate cancerPathological examinationClinical outcomesCure rateCancer recurrence